We have examined the effects of several PGs on the synthesis and release of the atrial natriuretic peptide (ANP) in vivo and in vitro. PGFF2, infusion in anesthetized rats resulted in a significant increase in plasma immunoreactive (ir) ANP levels in vivo despite effecting only modest changes in hemodynamics.
Introduction
The atrial natriuretic peptide (ANP)' is a peptide hormone that possesses potent bioactivity in the cardiovascular and renal systems (1, 2) . Secretion of this peptide by the cardiac 1 . Abbreviations used in this paper: ANP, atrial natriuretic peptide; CAT, chloramphenicol acetyltransferase; CVP, central venous pressure; 5FS, 5' flanking sequence; h, human; HR, heart rate; IBMX, isobutylmethylxanthine; irANP, immunoreactive ANP; MAP, mean arterial blood pressure; proANP, ANP prohormone.
atria is regulated by a number of hormones (3) (4) (5) (6) and neurotransmitters (7, 8) , as well as by factors that affect myocardial wall tension (9-1 1).
PGs are eicosanoid products of arachidonic acid metabolism produced by the enzyme cyclooxygenase. They are known to affect a variety of intracellular second messenger systems, possibly through interaction with specific PG receptors on the cell surface (12) . They are important regulators of cardiovascular and renal physiology with potent effects on platelet function, vascular reactivity, renal blood flow, and the handling of salt and water in the kidney (13) . PGs have largely been excluded as playing an important role in mediating ANP bioactivity (14) (15) (16) , but their role in regulating ANP release has been studied only to a limited degree (17).
This study was designed to investigate the regulation of immunoreactive ANP (irANP) secretion and ANP gene expression by the PGs in vivo and in vitro, and to assess the potential role of cyclooxygenase products in mediating stretch-induced ANP secretion. The findings support the hypothesis that PGs stimulate irANP release directly at the level of the myocardial cell and suggest their involvement in promoting stretch-dependent release of the hormone. In vivo studies. Female Sprague-Dawley rats (250-350 g) were anesthetized with 2% chloralose and 25% urethane (3 ml/kg i.p.). An intra-arterial PE-50 catheter was placed in the left carotid artery for measurement of mean arterial blood pressure (MAP). Catheters were also introduced into the right internal jugular vein for the measurement of central venous pressure (CVP) and into the left femoral vein for administration of volume and pharmacological agents. Catheter patency was maintained with periodic administration of heparinized saline.
To examine the effects of intravenous administration of PGF2. on circulating ANP levels, the following protocol was used (Fig. 1 A) . 1 ml of blood was collected in 10 mM EDTA at time 0 and placed on ice. 1 min later 0.5 ml of normal saline (vehicle) was given into the femoral line over 60 s. A second l-ml blood sample was taken 5 min later. After 15 min a third blood sample was drawn. 1 min later PGF2, (1 mg/kg in 0.5 ml of saline) was delivered into the femoral line. l-ml blood samples were taken 1 and 4 min later. Blood volume was replaced with an equal volume of normal saline. MAP, CVP, and heart rate (HR) were measured throughout the course of the experiment.
For the volume expansion studies anesthetized rats were instrumented as described above to monitor MAP, CVP, and HR. A l-ml blood sample was taken at time 0 and processed as described above. After 1 min an infusion of 5 cm3 of saline was delivered into the femoral vein over a 60-s period. Additional blood samples were taken 1 and 4 min later. After a 30-45-min re-equilibration period a fourth blood sample was taken. 1 min later an 8-cm3 saline infusion was delivered over 60 s. Blood samples were taken 1 and 4 min later. This protocol is schematicized in Fig. 1 B. For the indomethacin-treated group the drug (I mg/kg in 0.1 M Na2CO3) was administered 30 min before the 5-cm3 infusion.
Blood samples were centrifuged and plasma was decanted. 0.5 ml of plasma was extracted over a Sep-Pac C-18 column as described by Lang et al. (9) and dried under a nitrogen stream. The dessicated material was resuspended in 250 Ml of buffer and duplicate 100-,gl aliquots were assayed for irANP as described previously (18) .
Cell isolation and culture. Neonatal rat cardiocyte primary cultures, enriched for either atrial or ventricular cells, were prepared as described previously (5) using a modification of the protocol of Simpson and Savion (19) . Cells were cultured for 72 h in DME H21 containing 10% FCS and 0.1 mM bromodeoxyuridine, followed by 48 h in DME H21 containing 5% serum substitute lacking thyroxine and cortisol (20) , 5% stripped serum previously treated to remove endogenous thyroid and steroid hormone (21), 5 Mg/ml insulin, 5 Ag/ml transferrin, and 750 nM vitamin B12. Cells (15 X 103/well) were then subjected to the individual treatments described below in 200 ul of serum-free DME H21 medium containing 10% serum substitute, insulin, transferrin, and vitamin B12. Additives were dissolved in small amounts of ethanol or dimethylsulfoxide. Similar concentrations of these solvents were added to the control media. irANP analysis. Culture medium was collected and centrifuged at 1 1,000 g for 15 s to remove any cellular debris. The supernatant was decanted and stored frozen at -20'C until assayed. RIA was performed essentially as described previously (5) .
Size-exclusion HPLC analysis was carried out using a Bio-Sil Tsk-125 column (Bio-Rad Laboratories, Richmond, CA). 20-,ul samples were applied directly and eluted isocratically with 0.1 M Na2SO4 and 0.02 M NaH2PO4, pH 6.8, containing 0.1% Triton X-100 at a flow rate of 1 ml/min. The 0.5-ml fractions were monitored for irANP by RIA. ANP prohormone (proANP) was one-tenth as effective as ANP in displacing '251-ANP from the antibody. ProANP levels were corrected for this difference in immunoreactivity. The elution positions of proANP and ANP were determined using 1231-labeled recombinant human (h) proANP and rat ANP. Additional unlabeled protein standards were also used to calibrate the column.
Where appropriate, RIA data were subjected to analysis ofvariance and the Newman-Keuls test for significance.
RNA extraction and analysis. Cytoplasmic RNA was isolated and ANP mRNA transcripts were quantitated by nuclease S1 protection as described previously (5) .
Transfection of hANF chloramphenicol acetyltransferase (CAT) constructions. Plasmid construction for pSV.-lamin CAT and p(-2,500)-hANP CAT have been described previously (22) . The former is a promoterless construct in which the SV40 enhancer and promoter elements have been deleted (23) and replaced with a 400-bp fragment from the human lamin cDNA (22 (24) with 280 V at 250 ,F capacitance using a gene pulsar with capacitance extender (Bio-Rad Laboratories). Cells were incubated for 15 min at room temperature, then transferred to DME H21 containing 10% FCS and cultured in 100-mm dishes for 60 h. At that point the medium was changed to DME H21 containing 10% serum substitute plus transferrin, insulin, and vitamin B12 as described above. PGF2. or vehicle was added to each plate and the incubations were continued for 8 h. At that point cells were collected, cytoplasmic extracts were made, and equivalent quantities ofcytoplasmic protein were assayed for CAT activity by TLC as described (22) . Levels of the acetylated forms of chloramphenicol were quantitated by identifying, excising, and counting (by liquid scintillation) the appropriate spot(s) on the TLC plate.
Results
To assess the role of eicosanoids in the regulation of ANP secretion, we examined the effect of intravenous administration of PGF2a (1 mg/kg) on the levels of circulating irANP in vivo. As shown in Fig. 2 A, PGF2a effected a significant increase in plasma irANP levels within 2 min of administration. Infusion ofan equivalent volume ofnormal saline was without effect. PGF2a administration also effected modest increases in MAP and CVP, although neither was statistically significant relative to the preinfusion (i.e., time 0) levels in the same (i.e., PGF2a-treated) group. HR, on the other hand, decreased sig- Fig. 3 , the PGs proved to be potent stimulators of irANP release. PGF2a effected a dose-dependent increase in release of irANP from these cultures after 24 h of incubation (Fig. 3 A) . It is noteworthy that the inclusion of isobutylmethylxanthine (IBMX), a phosphodiesterase inhibitor that amplifies agonist-stimulated cAMP accumulation in a number of systems, resulted in a partial reduction rather than an amplification of the PGF2a effect. irANP in the atrial cell culture media increased as a function of time (Fig. 4 A) in the presence or absence of PGF2a. The secretagogue effect of the PG was apparent after 24 h of exposure to the drug and remained statistically significant thereafter. PGE2 (Fig. 3 B) had a more modest effect on irANP release, while prostacyclin (PGI2, Fig. 3 C) had no effect on ANP secretion under the conditions examined. Several laboratories have shown previously that primary cultures of neonatal cardiocytes release predominately proANP into the culture medium (25, 26) . To provide assurance that the PGs were increasing media irANP by stimulating release of cellular proANP, rather than by stimulating the processing of proANP to another, more immunoreactive, ANP form, HPLC analysis of culture media was carried out. As shown in Fig. 4 B, the bulk of irANP in either the control or the PGF2.-treated cells migrated with proANP, arguing against a significant effect of the PG on the conversion of proANP to ANP.
The reduction of PGF2&-stimulated irANP release in the presence of the phosphodiesterase inhibitor IBMX and the lack of effect of PG12, an eicosanoid that appears to function predominantly through activation of adenylate cyclase, suggest that the stimulatory effect is not mediated through a cAMP-dependent mechanism. To explore this further we examined the effects oftwo cAMP-dependent agonists on irANP secretion. As shown in Fig. 5 , administration of either 8-bromo-cAMP or forskolin, a direct activator of the membrane-bound adenylate cyclase, resulted in an inhibition of basal irANP release. Similarly, when forskolin was administered coincident with PGF2a, a modest reduction in agonist activity was seen. Taken together, these findings support the hypothesis that PG-mediated increments in irANP release do not operate through a cAMP-dependent mechanism. They also suggest that under the experimental conditions used in these studies, cAMP may act to suppress rather than stimulate ANP secretion.
To explore the mechanism of the PGF2a effect further we assessed the capacity of the eicosanoid to synergize with other secretogogues in promoting ANP release. As shown in Fig. 6 A, inclusion of increasing concentrations of potassium ion alone in the culture medium led to a dose-dependent increment in irANP release. Addition ofPGF2a resulted in a further increase in irANP release at each concentration of extracellular potassium, suggesting that these agents act through independent pathways in promoting granule release. The PGF2, effect was not dependent on the presence of calcium in the culture medium (Fig. 6 B) . The The effect on secretion of irANP was paralleled by an increase in the expression of the rat ANP gene. As shown in Fig.  7 , treatment with PGF2, or PGE2 resulted in a stimulation of ANP mRNA levels over a dose range that was similar to that found for secretion of the peptide. Again the effect was apparent in atrial (Fig. 7 A) and ventricular (Fig. 7 B) Next, we asked whether endogenous PG production contributes significantly to the basal release of irANP in the cardiocyte primary cultures. As shown in Fig. 8 , high concentrations (1o-4 M) of meclophenamate, naproxen, or indomethacin resulted in significant reductions in irANP release. These findings imply that PG production, even in these static cultures, may play a role in maintaining basal irANP secretion.
Finally, we asked whether PGs might play a role in fostering stretch-induced release of the peptide from the cardiac atria. Several groups (27) (28) (29) have identified significant levels of PGs in atrial tissue, and stretch has been shown to increase PG release in a number ofother systems (30, 31). To approach this question we used the protocol outlined in Fig. 1 B to volume-expand anesthetized rats in vivo, monitoring the changes in plasma ANP levels as a function ofchanges in MAP and CVP. As shown in Fig. 9 , pretreatment of rats with indomethacin (1 mg/kg) resulted in a -50% reduction in the increment in plasma irANP levels 2 and 5 min after an 8-cm3 volume infusion, supporting a role for endogenous PG production in regulating or modulating the ANP secretory response to increased atrial tension. This attenuation of the plasma ANP response to volume infusion occurred despite the fact that the changes in CVP and MAP were very similar in the indomethacin-treated and control animals.
Discussion
The findings presented above demonstrate that the PGs, particularly PGF2,, are capable of increasing ANP secretion in vivo and in vitro, lending further support to the importance of these agents in the regulation of fluid and electrolyte balance and cardiovascular homeostasis (1, 3). Although PGF2a administration resulted in modest changes in CVP and MAP in our in vivo preparation, it does not seem likely that these changes alone could account for the increase in plasma ANP. As shown in Fig. 9 A, a 5-ml volume infusion resulted in similar alterations in hemodynamics without significantly affecting plasma ANP levels. These findings imply that at least a portion of the PGF2a effect is independent of changes in central hemodynamics. The in vitro studies support an interaction directly at the level of the myocardial cell. While the absolute magnitude ofthe PGF2a induction in vitro varied from 2-to as much as 10-fold, the stimulatory effect was consistently found in each of six individual experiments (data not shown). PGE2 occasionally gave statistically significant responses of a similar magnitude, but in general, as shown in Fig. 2 B, the effect was 50% of that seen with PGF2a. In addition, higher doses of PGE2 (1O-5 vs. 10-7 M for PGF2a) were required to achieve maximal secretion. We also tested PGI2 (prostacycin) for effects on release of the peptide and/or ANP mRNA level and found none; however, given the very short half-life of this agent in many biological systems and the extended time course ofmost ofour studies, a possible role for PGI2 in the regulation of ANP secretion and/or gene expression cannot be excluded with certainty.
PGs are known to function through a number of different second messenger pathways. The best studied among these is the activation of adenylate cyclase (32), presumably through a PG receptor on the cell surface. In general, PGs of the E series are more effective than those of the F series in promoting this activation (32) . Noteworthy, inclusion of IBMX at concentrations that promote agonist-stimulated cAMP accumulation in other systems resulted in a reduction in irANP release, implying that, if anything, intracellular cAMP may act to reduce rather than stimulate secretion ofthe peptide in the presence of the PG. This hypothesis is supported by the fact that 8-bromo-cAMP and forskolin, two agents that promote cAMPdependent activity through separate mechanisms, reduced basal irANP release, and in the latter case PGF2a-stimulated release, from atrial cardiocyte cultures. By inference this would suggest that an alternative second messenger system (e.g., intracellular calcium or phosphoinositide turnover) is involved in mediating the PG effect.
Effects of PGF2A. on irANP secretion were first evident after 24 h, a time point that is probably dominated by effects on synthesis rather than release of preformed storage pools. The absence of stimulation at the earlier time points probably reflects the lack of sensitivity of our assay system in detecting small changes in secretory activity. In recent pilot studies, using atriocytes cultured on an extracellular matrix, we have been able to demonstrate PGF2a-mediated increments in secretory activity within 15 min of administration of the eico-A B the stability of the secreted ANP peptide or the ANP mRNA are not excluded by the present study and could contribute to their respective steady-state levels. The data also indicate that the hANP gene shares with its counterpart in the rat a sensitivity to PG stimulation, and that at least some of the recognition signals governing this stimulation at the genetic level are encoded within -2,500 bp of 5'FS. These data raise some intriguing questions regarding the physiological relationship of PG production to ANP secretion. PGs are known to be released from vascular tissue in response to stretch in vitro (30, 31), and stretch or tension is thought to be the dominant modulator of ANP secretion from the cardiac atria in vivo (9, 10) and in vitro (1 1). In addition, the right atrium can be a significant source of endogenous PG production (27) (28) (29) , raising the possibility that the PGs or related products could serve as transduction mechanisms linking tension to ANP secretion. Treatment of our cultured cardiocytes with either indomethacin, meclophenamate, or naproxen effected a modest reduction in the basal rate of irANP secretion. However, in each case the concentration of cyclooxygenase inhibitor required to demonstrate the inhibition was quite high, suggesting that, at least in our static primary cultures, basal release is not heavily PG dependent. Nevertheless, it remains possible that local production of PGs in a more physiological setting could serve as an important modulator of ANP release on either an autocrine or a paracrine basis, a hypothesis that is supported to some degree by the in vivo studies presented in Fig. 9 (see below) . Loss of the capacity for PG production in myocardial (i.e., an autocrine mechanism) or mesenchymal cells (i.e., a paracrine mechanism) due to subtle alterations in cellular physiology related to placing the cells in culture (e.g., absence of pulsatile tension) or, alternatively, to exclusion of the relevant PG-producing cell from the primary cultures, could account for the relative ineffectiveness of the cyclooxygenase inhibitors in vitro.
Another interesting finding obtained from the in vivo studies relates to the effects ofthe PGs on HR. As shown in Fig. 1 , a modest and nonsignificant elevation in MAP seen after PGF2a administration was accompanied by a reduction in HR of almost 100 beats per minute, presumably resulting from activation of the baroreceptor reflex. A similar increase in MAP seen after a 5-or 8-ml volume infusion (Fig. 9 ) was accompanied by a much smaller decrease in HR (i.e., -20-30 beats per minute). More importantly, pretreatment of the animals with indomethacin eliminated the baroreceptor-mediated reflex bradycardia seen with the 5-ml infusion and severely truncated that seen with the 8-ml infusion. This suggests that PGs positively regulate or amplify signals originating in the arterial baroreceptors, structures which, like the ANP-producing cardiocytes, are responsible for transducing tension or stretch-derived information into a second effector system.
Myocardial cells may also respond to PGs carried to the heart from extracardiac sites of production (e.g., vascular endothelium or renal medulla). Under physiological conditions most PGs, with the exception of prostacyclin, are cleared in a single passage through the pulmonary circulation. However, based on data presented in Fig. 2 , it is apparent that this clearance function can be saturated to some extent when large nonphysiological concentrations of eicosanoid are administered. These considerations take on potential relevance when one considers the underlying pathophysiology in patients with Bartter's syndrome (33). Bartter's syndrome is a clinical disorder characterized by hypovolemia, hypokalemia, normal blood pressure, vascular resistance to angiotensin and other vasopressors, an abnormality in renal chloride handling, and an elevation in renal PG production. These patients have also been shown to have inappropriately elevated plasma ANP levels (34) (35) (36) . The combination of hypovolemia, elevated ANP levels, increased PG production, and reversibility ofeach these features with indomethacin treatment suggests that the elevations in plasma ANP could result from overproduction of renal PGs in these patients (34) (35) (36) . The findings described in this study raise the intriguing possibility that such an effect could arise from direct stimulation of the ANP-producing atrial cardiocytes by PGs produced in the kidney. It is also noteworthy that a number of features of the syndrome (e.g., hypovolemia and resistance to vasopressor bioactivity) which have, in large part, been attributed to the PGs, represent biological effects that are shared in common with ANP. Overproduction of ANP could serve to amplify PG-dependent activity at the periphery and contribute to the phenotype of the syndrome.
In summary, we have demonstrated that PGs have a direct stimulatory effect on ANP secretion and ANP gene expression in primary cultures of myocardial cells. Our findings suggest that these eicosanoids may play an important role in the physiological mechanism linking stretch to ANP release. PG-mediated ANP release may also be ofimportance in pathophysiological states characterized by PG overproduction, either locally (e.g., in ischemic myocardium) or in extracardiac sites (e.g., the renal medulla).
